- TORL BioTherapeutics Announces Initial Results of Novel Claudin 6 (CLDN6) Targeted Antibody Drug Conjugate (ADC) TORL-1-23 Selected for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Careismatic Brands, Inc. Acquires BALA Footwear
- Astellas to revisit fatal neuromuscular condition in partnership with startup Kate Therapeutics
- New study finds continuing immunotherapy once cancer progresses doesn’t work and could cause harm
- Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases
- Fitness & Yoga Campus, Camp Los Angeles, Warms Up for Summer Expansion in West L.A.
- Don’t Mess with Success: U.S. Immunology Treaters Resistant to Switching Stable Humira Patients to Biosimilars, According to Spherix Global Insights
- Upstream Bio raises $200M in new financing round to get asthma drug to PhIII
- Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences
- 212 Local Girl Scouts Honored for Earning the Gold Award, the Highest Award in Girl Scouting